NASDAQ:FURX

(FURX) (FURX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FURX stock logo

About (FURX) Stock (NASDAQ:FURX)

Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.

FURX Stock News Headlines

Move Your Money Before May 22
The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.
Man arrested for Worcester bank robbery
Move Your Money Before May 22
The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.
Cirque Italia returns to Memphis
David Einhorn: Long on Apple
See More Headlines
Receive FURX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (FURX) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:FURX
CUSIP
36106P10
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

FURX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of (FURX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (FURX) investors own include Pretium Resources (PVG), Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR), Baidu (BIDU), Salesforce (CRM), Cisco Systems (CSCO), Gilead Sciences (GILD), Alphabet (GOOG), Incyte (INCY) and InvenSense (INVN).

This page (NASDAQ:FURX) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners